Current problems in cancer. Case reports最新文献_第9页

The use of ctDNA MRD precision medicine surveillance after definitive treatment of early-stage, high-risk breast cancer in a radiation oncology practice: A case series 放射肿瘤学实践中早期高危乳腺癌确诊治疗后ctDNA MRD精准医学监测的应用：病例系列

Current problems in cancer. Case reports Pub Date : 2024-05-11 DOI: 10.1016/j.cpccr.2024.100295

Michael A. Durka , Eemon Tizpa , Brian D. Lawenda

{"title":"The use of ctDNA MRD precision medicine surveillance after definitive treatment of early-stage, high-risk breast cancer in a radiation oncology practice: A case series","authors":"Michael A. Durka , Eemon Tizpa , Brian D. Lawenda","doi":"10.1016/j.cpccr.2024.100295","DOIUrl":"10.1016/j.cpccr.2024.100295","url":null,"abstract":"<div><p>Standard of care for patients with early-stage breast cancer typically does not use systemic surveillance or imaging studies following the administration of definitive treatment. However, the use of a circulating tumor DNA (ctDNA) test may provide an opportunity for early detection of cancer recurrence, particularly in patients with high-risk or aggressive forms of the disease. We present two cases of early-stage triple-negative breast cancer (TNBC) in which ctDNA screening facilitated early detection of recurrence prior to detection by imaging. As a result, treatment was initiated sooner than would have been possible in the absence of ctDNA screening.</p><p>These cases underscore the potential utility of ctDNA screening integration within a radiation oncology practice for the detection of recurrent breast cancer, and how their use in routine clinical practice could benefit patients. We also provide a review of the current literature on ctDNA testing, including its benefits and limitations. While there is currently insufficient data to support the routine use of ctDNA screening in all patients, we speculate on specific patient populations that may derive the greatest benefit from this innovative diagnostic tool.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"14 ","pages":"Article 100295"},"PeriodicalIF":0.0,"publicationDate":"2024-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000188/pdfft?md5=66906b35790af2ba622b686341d79661&pid=1-s2.0-S2666621924000188-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141042517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combination pembrolizumab and lenvatinib in metastatic mismatch repair deficient adenocarcinoma of Mullerian origin: A case report Pembrolizumab和仑伐替尼联合治疗转移性错配修复缺陷缪勒源性腺癌：病例报告

Current problems in cancer. Case reports Pub Date : 2024-05-10 DOI: 10.1016/j.cpccr.2024.100297

Jessica M. Velasquez, Matthew Flint, Caitlin Carr, Samantha Cohen

{"title":"Combination pembrolizumab and lenvatinib in metastatic mismatch repair deficient adenocarcinoma of Mullerian origin: A case report","authors":"Jessica M. Velasquez, Matthew Flint, Caitlin Carr, Samantha Cohen","doi":"10.1016/j.cpccr.2024.100297","DOIUrl":"10.1016/j.cpccr.2024.100297","url":null,"abstract":"<div><h3>Background</h3><p>For mismatch repair protein deficient (dMMR) endometrial cancer (EC), first line therapy remains platinum-based chemotherapy. For dMMR EC that has progressed on standard first line platinum containing chemotherapy, treatment with programmed death ligand-1 (PD-1) inhibitors such as pembrolizumab have become integral to second line therapy. The challenging question remains, however, what the next best step is when these treatments fail.</p></div><div><h3>Case</h3><p>Here we report the case of a 71-year-old female who developed disease recurrence more than 20 years after surgical treatment for early stage dMMR endometrioid EC, with subsequent progression of disease on second line pembrolizumab therapy; however displayed excellent response to third line treatment with lenvatinib and pembrolizumab.</p></div><div><h3>Conclusion</h3><p>Consensus regarding third line treatment for patients with dMMR EC who progress on single agent PD-1 inhibitors after platinum-based chemotherapy failure remains unclear. While single agent pembrolizumab has demonstrated the greatest efficacy for dMMR disease, this case demonstrates a patient who had progression of disease on single agent pembrolizumab, however had excellent response with combination pembrolizumab and lenvatinib. Further study is warranted to assess the efficacy of this regimen for advanced or recurrent dMMR EC.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"14 ","pages":"Article 100297"},"PeriodicalIF":0.0,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000206/pdfft?md5=53ec6027d213bdcae4889c6a034bcb38&pid=1-s2.0-S2666621924000206-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141044418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rare case of epithelioid angiosarcoma presenting as nodular pulmonary opacities in a 23-year-old woman 一名 23 岁女性罕见的上皮样血管肉瘤结节性肺不张病例

Current problems in cancer. Case reports Pub Date : 2024-04-21 DOI: 10.1016/j.cpccr.2024.100290

Zein Kattih , Jonathan Moore , Alain Borczuk , Ann E. Tilley

引用次数: 0

Simultaneous PTHrp- and calcitriol-mediated hypercalcemia associated with probable spontaneous transformation of lung adenocarcinoma to squamous cell carcinoma: A case report 同时由 PTHrp 和降钙素三醇介导的高钙血症与肺腺癌可能自发转化为鳞癌有关：病例报告

Current problems in cancer. Case reports Pub Date : 2024-04-15 DOI: 10.1016/j.cpccr.2024.100289

Run Yu

{"title":"Simultaneous PTHrp- and calcitriol-mediated hypercalcemia associated with probable spontaneous transformation of lung adenocarcinoma to squamous cell carcinoma: A case report","authors":"Run Yu","doi":"10.1016/j.cpccr.2024.100289","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100289","url":null,"abstract":"<div><p>Hypercalcemia is a common paraneoplastic syndrome. Malignancies cause hypercalcemia by various mechanisms. Usually a single mechanism underlies paraneoplastic hypercalcemia. Two simultaneous mechanisms associated with one malignancy, however, are occasionally encountered. Here a rare case is reported to describe simultaneous PTHrp- and calcitriol-mediated hypercalcemia associated with probable spontaneous transformation of lung adenocarcinoma to squamous cell carcinoma. This 81-year-old male with history of resected lung adenocarcinoma developed hypercalcemia. The peak albumin-corrected calcium was 13.4 mg/dL (normal 8.6–10.4) with ionized calcium 1.70 mmol/L (normal 1.09–1.29). Laboratory tests showed PTH 7 pg/ml (normal 11–51), PTHrP 43.7 pmol/L (normal <2.3), 25-hydroxyvitamin D 33 ng/ml (normal 20–50), 1,25-dihydroxyvitamin D 71.0 pg/ml (19.9–79.3), TSH 3.1 µIU/mL (normal 0.3–4.7). CT showed new right lower lobe lung masses, paraesophageal and pericaval lymph nodes, and a cranial lesion. Biopsy of a lung mass revealed predominantly squamous cell carcinoma. He was treated with intravenous fluid and zoledronate with normalization of calcium levels. Vitamin D supplement was discontinued. The patient's clinical condition deteriorated before chemotherapy was started. He died shortly after comfort care was initiated. Pursuing multiple causes of paraneoplastic hypercalcemia is worthwhile as the treatment towards each mechanism is different.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"14 ","pages":"Article 100289"},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000127/pdfft?md5=cedc7f8438be9a1bb9c951b6b5166d87&pid=1-s2.0-S2666621924000127-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140554082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges in managing chronic kidney disease with simultaneous renal transplant immunosuppressant induced buccal squamous cell carcinoma and gastric Burkitt's like lymphoma: A case report 同时患有肾移植免疫抑制剂诱发的口腔鳞状细胞癌和胃伯基特样淋巴瘤的慢性肾病患者的治疗挑战：病例报告

Current problems in cancer. Case reports Pub Date : 2024-04-04 DOI: 10.1016/j.cpccr.2024.100288

Syeda Sara Tajammul , Shruti Maheshwari , Javeria Munir , Khalil Al-Farsi , Ali Allawati , Zamzam Al Hashami , Layth Mula-Hussain

{"title":"Challenges in managing chronic kidney disease with simultaneous renal transplant immunosuppressant induced buccal squamous cell carcinoma and gastric Burkitt's like lymphoma: A case report","authors":"Syeda Sara Tajammul , Shruti Maheshwari , Javeria Munir , Khalil Al-Farsi , Ali Allawati , Zamzam Al Hashami , Layth Mula-Hussain","doi":"10.1016/j.cpccr.2024.100288","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100288","url":null,"abstract":"<div><p>Immunodeficiency is associated with higher cancer incidence, especially in transplanted patients; however, it is unknown whether there is a link between immunodeficiency and the development of multiple primary malignancies. Immunosuppressive drugs may either indirectly potentiate the effect of carcinogens or directly damage the DNA. Skin cancers are the most common malignancies diagnosed in renal transplant recipients. Management of immunosuppression in recipients of transplants who are living with cancer is complex and challenging. A concerted approach between transplant professionals, oncologists, and allied health professionals is therefore needed to ensure optimal care for transplant recipients who are developing immunodeficiency-induced malignancies. Here, we report a challenging case that presented with two simultaneous malignancies (buccal squamous cell carcinoma and gastric Burkitt's-like lymphoma) after nine years of being on immunosuppressants after the kidney transplant. The patient tolerated his cancer treatments with some grade II-III toxicities and is currently a two-year disease-free survivor. Focusing on the curative intent approaches for the two cancers with the adjustment of the immunosuppressant medications, besides the complications associated with these radical treatments, is worthy of being presented to the transplant and oncology teams globally.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"14 ","pages":"Article 100288"},"PeriodicalIF":0.0,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000115/pdfft?md5=848d60d4cfd716d236f3f30a83a3b20e&pid=1-s2.0-S2666621924000115-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140533884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Completed durable response of advanced endometrial cancer treated with pembrolizumab without surgical intervention or systemic chemotherapy: A case report 使用 pembrolizumab 治疗晚期子宫内膜癌，未进行手术干预或全身化疗，却完成了持久应答：病例报告

Current problems in cancer. Case reports Pub Date : 2024-03-17 DOI: 10.1016/j.cpccr.2024.100285

Anusha Adkoli , Rodrigo Alcorta Proaño , Eugenia Girda

{"title":"Completed durable response of advanced endometrial cancer treated with pembrolizumab without surgical intervention or systemic chemotherapy: A case report","authors":"Anusha Adkoli , Rodrigo Alcorta Proaño , Eugenia Girda","doi":"10.1016/j.cpccr.2024.100285","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100285","url":null,"abstract":"<div><p>Endometrial cancer remains the most common gynecologic malignancy in the United States. Novel molecular targets are being explored for treatment of advanced uterine. Molecular targets in signaling cascades have been identified including immune checkpoint inhibitors. This is a case of 63-year-old G0 with locally advanced unstaged undifferentiated/dedifferentiated TMB-H/MSI endometrial cancer, who had progression of disease after neoadjuvant radiation therapy. She was intolerant of systemic chemotherapy and declined surgical intervention but had subsequent complete response after 9 cycles of pembrolizumab. She has remained disease free for a total of 30 months (about 2.5 years) of follow up. Standard of care for advanced uterine cancer includes multimodality treatment with surgery, radiation, and systemic chemotherapy. This patient's response to treatment demonstrates that immunotherapy as an upfront treatment may be a reasonable alternative for patients with endometrial cancer with specific molecular profile regardless of histology.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"14 ","pages":"Article 100285"},"PeriodicalIF":0.0,"publicationDate":"2024-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000085/pdfft?md5=928435e2c6ff4093a59dd325e40539ab&pid=1-s2.0-S2666621924000085-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140181394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Merkel cell carcinoma of the breast: A case report 乳腺梅克尔细胞癌：病例报告

Current problems in cancer. Case reports Pub Date : 2024-03-16 DOI: 10.1016/j.cpccr.2024.100287

Catherine McNulty , Shabnam Mortazavi , Joseph Giessinger , Sepehr Hamidi

引用次数: 0

Detection of a co-mutation in the epidermal growth factor receptor gene exon 20 H773L/V774M by FoundationOne test and treatment with osimertinib: A case report 通过FoundationOne检测发现表皮生长因子受体基因第20外显子H773L/V774M的共突变，并接受奥希替尼治疗：病例报告

Current problems in cancer. Case reports Pub Date : 2024-03-08 DOI: 10.1016/j.cpccr.2024.100286

Hiroshi Yoshida , Hiroaki Ozasa , Kentaro Hashimoto , Yusuke Shima , Keiichiro Suminaga , Hitomi Ajimizu , Takashi Nomizo , Hironori Yoshida , Masahiro Yoshioka , Masashi Kanai , Takehito Shukuya , Manabu Muto , Toyohiro Hirai

{"title":"Detection of a co-mutation in the epidermal growth factor receptor gene exon 20 H773L/V774M by FoundationOne test and treatment with osimertinib: A case report","authors":"Hiroshi Yoshida , Hiroaki Ozasa , Kentaro Hashimoto , Yusuke Shima , Keiichiro Suminaga , Hitomi Ajimizu , Takashi Nomizo , Hironori Yoshida , Masahiro Yoshioka , Masashi Kanai , Takehito Shukuya , Manabu Muto , Toyohiro Hirai","doi":"10.1016/j.cpccr.2024.100286","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100286","url":null,"abstract":"<div><p>Among cases of non-small cell lung cancer (NSCLC) with EGFR mutations, NSCLC with deletions in EGFR exon 19 or 21 L858R account for 85 %. Frequency of NSCLC with minor mutations in EGFR is about 9 %, whilst EGFR exon 20 insertion mutation account for 6 % of the cases, determining it as a rare mutation. In this case, minor EGFR mutation and compound mutation EGFR H773L/V774M, were detected. Oncomine Dx target test (Oncomine), FoundationOne, and Amoy Dx polymerase chain reaction panel (Amoy 9-in-1 kit) were used as companion diagnostic tests. FoundationOne was the only one able to detect EGFR exon 20 H773L/V774M mutations. Drug therapy for NSCLC with compound mutations in EGFR exon 20 is not yet established. Unsuccessful treatments with EGFR-TKIs such as Erlotinib, Gefitinib, and Afatinib have been reported. There have also been reports of successful treatments with Osimertinib in combination with Bevacizumab. In the presented case, Osimertinib monotherapy was successful in treating NSCLC with EGFR exon 20 compound mutation. Osimertinib, therefore, has the potential to treat NSCLC with EGFR exon 20 H773L/V774M mutation, and can be a key drug for treating EGFR rare mutations.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"14 ","pages":"Article 100286"},"PeriodicalIF":0.0,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000097/pdfft?md5=747e780082018d7614de042efcf5d883&pid=1-s2.0-S2666621924000097-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140134053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plasma cfDNA in Carcinoma of unknown primary: A case series 血浆 cfDNA 在不明原发癌中的应用：一个病例系列

Current problems in cancer. Case reports Pub Date : 2024-02-10 DOI: 10.1016/j.cpccr.2024.100283

Rajat Thawani , Ajay Mohinani , Mason McLellan , Nima Nabavizadeh , Sean Goodyear , Adel Kardosh

引用次数: 0

Blue-ink tattoo reaction associated with immune checkpoint inhibitor treatment of metastatic colorectal cancer, a case report 与免疫检查点抑制剂治疗转移性结直肠癌相关的蓝墨水纹身反应，一份病例报告

Current problems in cancer. Case reports Pub Date : 2024-02-04 DOI: 10.1016/j.cpccr.2024.100281

Nolan Holley , Jessica Patterson , Michael Kolodney , Joanna Kolodney

{"title":"Blue-ink tattoo reaction associated with immune checkpoint inhibitor treatment of metastatic colorectal cancer, a case report","authors":"Nolan Holley , Jessica Patterson , Michael Kolodney , Joanna Kolodney","doi":"10.1016/j.cpccr.2024.100281","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100281","url":null,"abstract":"<div><p>Immune checkpoint inhibitors (ICIs) have revolutionized the field of oncology and transformed the management of many malignancies, especially for patients with metastatic disease. Dermatologic toxicities are among the most common immune-related adverse events (irAEs) of ICIs and can manifest in various ways. We report the case of a 56-year-old male with metastatic colorectal cancer treated with ipilimumab and nivolumab who then developed dermatologic abnormalities confined to the blue-ink regions of his long-standing multicolored tattoos on multiple areas of his body. The patient's reaction resolved after intralesional injection of triamcinolone acetonide. Tattoo reactions associated with ICI treatment are rare, and to our knowledge, there have been no published cases of dermatologic irAEs isolated to blue-pigmented areas of multicolored tattoos. It is of great importance to have awareness of the possibility of this type of reaction and to provide appropriate care for patients undergoing treatment with ICIs.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"13 ","pages":"Article 100281"},"PeriodicalIF":0.0,"publicationDate":"2024-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000048/pdfft?md5=d5613591666210d0658f522c5ce12bbc&pid=1-s2.0-S2666621924000048-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139719195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0